Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia

dc.contributor.authorTyan, Paul I.
dc.contributor.authorRadwan, Amr H.
dc.contributor.authorEid, Assaad A.
dc.contributor.authorHaddad, Anthony G.
dc.contributor.authorWehbe, David
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentAnatomy, Cell Biology, and Physiological Sciences
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:36:31Z
dc.date.available2025-01-24T11:36:31Z
dc.date.issued2014
dc.description.abstractThe term Nontransfusion dependent thalassaemia (NTDT) was suggested to describe patients who had clinical manifestations that are too severe to be termed minor yet too mild to be termed major. Those patients are not entirely dependent on transfusions for survival. If left untreated, three main factors are responsible for the clinical sequelae of NTDT: ineffective erythropoiesis, chronic hemolytic anemia, and iron overload. Reactive oxygen species (ROS) generation in NTDT patients is caused by 2 major mechanisms. The first one is chronic hypoxia resulting from chronic anemia and ineffective erythropoiesis leading to mitochondrial damage and the second is iron overload also due to chronic anemia and tissue hypoxia leading to increase intestinal iron absorption in thalassemic patients. Oxidative damage by reactive oxygen species (generated by free globin chains and labile plasma iron) is believed to be one of the main contributors to cell injury, tissue damage, and hypercoagulability in patients with thalassemia. Independently increased ROS has been linked to a myriad of pathological outcomes such as leg ulcers, decreased wound healing, pulmonary hypertension, silent brain infarcts, and increased thrombosis to count a few. Interestingly many of those complications overlap with those found in NTDT patients. © 2014 Paul I. Tyan,et al.
dc.identifier.doihttps://doi.org/10.1155/2014/350432
dc.identifier.eid2-s2.0-84904813744
dc.identifier.pmid25121095
dc.identifier.urihttp://hdl.handle.net/10938/28616
dc.language.isoen
dc.publisherHindawi Publishing Corporation
dc.relation.ispartofBioMed Research International
dc.sourceScopus
dc.subjectAnoxia
dc.subjectBlood transfusion
dc.subjectHumans
dc.subjectIron overload
dc.subjectNadph oxidase
dc.subjectReactive oxygen species
dc.subjectThalassemia
dc.subjectGlobin
dc.subjectReactive oxygen metabolite
dc.subjectReduced nicotinamide adenine dinucleotide phosphate oxidase
dc.subjectReduced nicotinamide adenine dinucleotide phosphate oxidase 2
dc.subjectReduced nicotinamide adenine dinucleotide phosphate oxidase 4
dc.subjectAnemia
dc.subjectBrain infarction
dc.subjectErythropoiesis
dc.subjectHemolytic anemia
dc.subjectHuman
dc.subjectHypoxemia
dc.subjectIntestine absorption
dc.subjectIron absorption
dc.subjectNontransfusion dependent thalassaemia
dc.subjectOsteoporosis
dc.subjectOxidative stress
dc.subjectPulmonary hypertension
dc.subjectReview
dc.subjectThrombosis
dc.subjectWound healing
dc.subjectWound healing impairment
dc.subjectMetabolism
dc.subjectPathology
dc.titleNovel approach to reactive oxygen species in nontransfusion-dependent thalassemia
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2014-10722.pdf
Size:
1.93 MB
Format:
Adobe Portable Document Format